Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

VSTM

Verastem Inc

May 02 • 04:00PM ET

10.36

Dollar change +0.38
Percentage change 3.81	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF AVSC

Index	-	P/E	-	EPS (ttm)	-4.08	Insider Own	19.05%	Shs Outstand	25.28M	Perf Week	12.43%
Market Cap	262.11M	Forward P/E	-	EPS next Y	-2.75	Insider Trans	-0.41%	Shs Float	20.48M	Perf Month	-13.52%
Income	-87.37M	PEG	-	EPS next Q	-1.03	Inst Own	47.84%	Short Float	3.94%	Perf Quarter	-15.43%
Sales	0.00M	P/S	-	EPS this Y	5.09%	Inst Trans	-	Short Ratio	5.77	Perf Half Y	64.97%
Book/sh	2.27	P/B	4.57	EPS next Y	26.95%	ROA	-71.39%	Short Interest	0.81M	Perf Year	98.47%
Cash/sh	5.46	P/C	1.90	EPS next 5Y	1.74%	ROE	-138.76%	52W Range	4.68 - 15.18	Perf YTD	27.27%
Dividend Est.	-	P/FCF	-	EPS past 5Y	24.76%	ROI	-73.33%	52W High	-31.75%	Beta	0.41
Dividend TTM	-	Quick Ratio	5.45	Sales past 5Y	-45.06%	Gross Margin	-	52W Low	121.37%	ATR (14)	0.58
Dividend Ex-Date	-	Current Ratio	5.45	EPS Y/Y TTM	11.24%	Oper. Margin	0.00%	RSI (14)	47.46	Volatility	4.94% 5.52%
Employees	73	Debt/Eq	0.53	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	28.79
Option/Short	Yes / Yes	LT Debt/Eq	0.52	EPS Q/Q	-3.51%	Payout	-	Rel Volume	0.56	Prev Close	9.98
Sales Surprise	-100.00%	EPS Surprise	-66.83%	Sales Q/Q	-	Earnings	Mar 14 AMC	Avg Volume	139.72K	Price	10.36
SMA20	-1.58%	SMA50	-8.71%	SMA200	7.78%	Trades		Volume	78,783	Change	3.81%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-21-23	Resumed	BTIG Research	Buy	$27
Sep-27-23	Initiated	B. Riley Securities	Buy	$21
Jun-15-23	Upgrade	Mizuho	Neutral → Buy	$24 → $36
Sep-07-22	Resumed	Alliance Global Partners	Buy	$6
Apr-29-22	Resumed	Cantor Fitzgerald	Overweight	$6 → $5
Apr-14-22	Initiated	RBC Capital Mkts	Outperform	$5
Mar-09-22	Initiated	Truist	Buy	$6
Jul-01-21	Initiated	Alliance Global Partners	Buy	$6
May-24-21	Upgrade	BTIG Research	Neutral → Buy	$8
Jun-20-19	Downgrade	BTIG Research	Buy → Neutral
May-10-19	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-13-18	Initiated	BTIG Research	Buy	$17
May-02-18	Initiated	Seaport Global Securities	Buy	$14
Mar-08-18	Initiated	B. Riley FBR, Inc.	Buy	$15
Sep-07-17	Reiterated	H.C. Wainwright	Buy	$6.50 → $10
Apr-13-17	Initiated	Oppenheimer	Outperform
Mar-24-17	Reiterated	H.C. Wainwright	Buy	$5 → $6.50
Sep-29-15	Downgrade	Raymond James	Strong Buy → Outperform
Sep-29-15	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-29-15	Downgrade	Jefferies	Buy → Hold

Show Previous Ratings

Apr-18-24 04:05PM	Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer (Business Wire) -5.63%
Apr-09-24 07:00AM	GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting (PR Newswire)
Apr-04-24 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.43%
Mar-18-24 07:00AM	Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer (Business Wire)
Mar-14-24 09:54PM	VSTM Stock Earnings: Verastem Misses EPS for Q4 2023 (InvestorPlace)
04:53PM	Loading…
04:53PM	Verastem: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates (Business Wire)
Mar-11-24 07:30AM	Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Womens Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs (Business Wire)
Mar-05-24 05:27PM	Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
04:30PM	Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024 (Business Wire)
Feb-15-24 03:12AM	Andreas Halvorsen's Viking Global Investors LP Bolsters Position in Verastem Inc (GuruFocus.com)
Feb-07-24 05:02PM	Director Robert Gagnon Sells 9,204 Shares of Verastem Inc (VSTM) (GuruFocus.com)
07:15AM	3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024 (InvestorPlace)
Jan-29-24 07:00AM	Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers (Business Wire) +7.12%
Jan-22-24 08:15AM	Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy (Zacks)
04:00PM	Loading…
Jan-18-24 04:00PM	Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC) (Business Wire) -6.48%
Jan-11-24 07:00AM	Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference (Business Wire)
Jan-05-24 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-18-23 07:00AM	Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics (Business Wire)
Dec-13-23 09:08AM	3 Off-the-Beaten-Path Stocks Poised for Substantial Growth (InvestorPlace) +10.67%
07:00AM	Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
Dec-03-23 04:17PM	Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential (InvestorPlace)
Nov-22-23 12:00PM	All You Need to Know About Verastem (VSTM) Rating Upgrade to Buy (Zacks)
Nov-13-23 07:00AM	New Healthcare Professional Component of Lets Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach (Business Wire)
Nov-08-23 05:52PM	Verastem: Q3 Earnings Snapshot (Associated Press Finance)
04:12PM	Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
Nov-07-23 07:00AM	First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer (Business Wire) +6.65%
Nov-06-23 07:00AM	Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population (Business Wire)
Oct-26-23 04:05PM	Verastem Oncology Strengthens Executive Leadership Team with Key Appointments (Business Wire)
Oct-18-23 04:50PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
12:30PM	Loading…
Oct-14-23 12:30PM	Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer (Business Wire)
Oct-06-23 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-28-23 02:15PM	Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit (Business Wire) -5.13%
Sep-05-23 07:00AM	Verastem Oncology to Participate in Upcoming Investor Conferences (Business Wire)
Sep-04-23 01:23PM	3 Penny Stocks That Can Triple Your Money in the Next 12 Months (InvestorPlace)
Aug-28-23 07:00AM	Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers (Business Wire)
Aug-08-23 05:46PM	Verastem: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
Jul-11-23 07:00AM	Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer (Business Wire)
Jul-10-23 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +9.50%
Jul-05-23 04:05PM	Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
Jun-16-23 05:00AM	Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Jun-15-23 04:06PM	Verastem Stock Is Outperforming 92% Of The Market And It Just Surged (Investor's Business Daily) +16.09%
04:00PM	Verastem Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
May-31-23 09:11AM	Verastem Oncology Announces Reverse Stock Split (Business Wire)
May-25-23 05:05PM	Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib (Business Wire)
May-16-23 07:00AM	Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors (Business Wire)
May-09-23 04:56PM	Verastem: Q1 Earnings Snapshot (AP Finance)
04:05PM	Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
May-02-23 07:45AM	Strong week for Verastem (NASDAQ:VSTM) shareholders doesn't alleviate pain of five-year loss (Simply Wall St.)
May-01-23 07:00AM	Verastem Oncology to Participate in Upcoming Investor Conferences (Business Wire) +12.65%
Apr-26-23 04:05PM	New Data from Interim Analysis of Verastem Oncologys RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting (Business Wire)
Apr-18-23 07:05AM	Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days (Business Wire)
Apr-06-23 05:39PM	7 Very Undervalued Penny Stocks to Buy in April 2023 (InvestorPlace) -6.12%
04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-15-23 07:00AM	New Verastem Oncology Initiative, Lets Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer (Business Wire)
Mar-14-23 04:05PM	Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress (Business Wire)
Feb-02-23 07:00AM	Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers (Business Wire) +8.65%
Jan-30-23 12:00PM	Verastem (VSTM) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) -5.80%
Jan-24-23 05:46PM	Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock (Business Wire)
05:45PM	Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
Jan-18-23 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-11-23 06:24AM	individual investors who own 37% along with institutions invested in Verastem, Inc. (NASDAQ:VSTM) saw increase in their holdings value last week (Simply Wall St.) +11.00%
Dec-15-22 04:30PM	Verastem Oncology Appoints Rob Gagnon to Board of Directors (Business Wire) -5.00%
Nov-08-22 08:22AM	Verastem Third Quarter 2022 Earnings: US$0.092 loss per share (vs US$0.13 loss in 3Q 2021) (Simply Wall St.)
Nov-03-22 04:05PM	Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress (Business Wire)
Oct-20-22 07:00AM	Verastem Oncology Appoints Anil Kapur to Board of Directors (Business Wire)
Oct-07-22 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.49%
Oct-04-22 07:00AM	Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates (Business Wire) -34.60%
Sep-19-22 09:31AM	10 Long-Term Stocks to Buy During Recessions (Insider Monkey)
Aug-23-22 12:23PM	Investors five-year losses grow to 64% as the stock sheds US$34m this past week (Simply Wall St.)
Aug-08-22 07:00AM	Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress (Business Wire) +7.56%
Jul-27-22 11:40AM	Is Verastem (NASDAQ:VSTM) Using Too Much Debt? (Simply Wall St.)
Jul-07-22 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.93%
Jun-27-22 11:17AM	What You Need To Know About Verastem, Inc.'s (NASDAQ:VSTM) Investor Composition (Simply Wall St.)
Jun-07-22 02:26PM	RBC Says Verastem Interim Analysis In Ovarian Cancer Reinforces Enthusiasm (Benzinga) +11.07%
Jun-06-22 07:00AM	Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian Cancer (Business Wire) -8.27%
May-19-22 06:00PM	7 Cheap Biotech Stocks to Buy Now (InvestorPlace) +5.13%
May-18-22 08:45AM	Verastem Oncology Awarded Pancreatic Cancer Action Networks First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer (Business Wire)
May-09-22 04:05PM	Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress (Business Wire) -9.52%
08:25AM	Precision BioSciences (DTIL) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Apr-04-22 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.99%
Mar-28-22 01:46PM	Verastem Announces $150M Debt Financing To Support VS-6766, Defactinib Development (Benzinga) +10.92%
07:05AM	Verastem Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress (Business Wire)
07:00AM	Verastem Oncology Provides Financial Update to Support Development of VS-6766 and Defactinib in RAS Pathway-Driven Tumors (Business Wire)
Mar-24-22 07:05AM	Verastem Oncology Names Preeminent Oncology Researcher Channing Der, PhD, to its Scientific Advisory Board (Business Wire)
Mar-01-22 07:52AM	Mirati (MRTX) Q4 Earnings and Sales Fall Short of Estimates (Zacks)
Feb-22-22 05:00AM	Verastem (NASDAQ:VSTM) investors are sitting on a loss of 62% if they invested three years ago (Simply Wall St.)
Feb-03-22 05:38PM	Kalos Management, Inc. Buys Vale SA, Sells Consensus Cloud Solutions Inc, Intuitive Surgical ... (GuruFocus.com) -7.59%
Jan-11-22 07:00AM	Verastem Oncology Outlines Key 2022 Strategic Priorities and Upcoming Catalysts for Advancing VS-6766 as a Backbone of Therapy for RAS Pathway-Driven Cancers (Business Wire)
Jan-07-22 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-04-22 04:05PM	Verastem Oncology to Participate in Upcoming Investor Conferences (Business Wire)
Nov-23-21 08:53AM	Mirati (MRTX), Verastem to Study Cancer Drugs for NSCLC (Zacks)
Nov-22-21 07:30AM	Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer (PR Newswire)
Nov-15-21 06:01AM	10 Best Biotech Stocks to Buy According to Mark Lamperts Biotechnology Value Fund (Insider Monkey)
Nov-14-21 08:53AM	10 Best Biotech Stocks Under $5 (Insider Monkey)
Nov-11-21 07:00AM	Verastem Oncology to Present at the Jefferies London Healthcare Conference (Business Wire) +10.57%
Nov-04-21 04:05PM	Verastem Oncology Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress (Business Wire)
09:25AM	11 Best Long-Term Stocks To Buy Now (Insider Monkey)
Oct-26-21 07:00AM	Verastem Oncology Appoints Michelle Robertson to Board of Directors (Business Wire)

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Calkins Daniel	Chief Financial Officer	Apr 05 '24	Sale	10.87	6	65	8,535	Apr 08 04:30 PM
Calkins Daniel	Chief Financial Officer	Mar 25 '24	Sale	12.02	25	300	8,541	Mar 27 04:30 PM
Calkins Daniel	Chief Financial Officer	Mar 20 '24	Sale	11.07	55	609	8,566	Mar 21 04:31 PM
Stuglik Brian M	Director	Mar 19 '24	Sale	10.38	273	2,834	89,640	Mar 20 05:32 PM
Paterson Dan	President and CEO	Mar 19 '24	Sale	10.38	182	1,889	86,490	Mar 20 05:34 PM
Gagnon Robert E.	Director	Mar 19 '24	Sale	10.38	130	1,349	27,391	Mar 20 05:36 PM
Stuglik Brian M	Director	Mar 18 '24	Sale	10.71	537	5,751	89,913	Mar 20 05:32 PM
Gagnon Robert E.	Director	Mar 18 '24	Sale	10.71	283	3,031	27,521	Mar 20 05:36 PM
Paterson Dan	President and CEO	Mar 18 '24	Sale	10.71	244	2,613	86,672	Mar 20 05:34 PM
Gagnon Robert E.	Director	Feb 06 '24	Sale	13.70	9,204	126,095	27,804	Feb 07 04:00 PM
Gagnon Robert E.	Director	Jan 12 '24	Sale	10.95	9,204	100,784	37,008	Jan 17 04:00 PM
Calkins Daniel	Chief Financial Officer	Jan 05 '24	Sale	8.50	6	51	8,621	Jan 09 04:03 PM
Calkins Daniel	Chief Financial Officer	Dec 26 '23	Sale	8.08	25	202	8,350	Dec 28 04:04 PM
Calkins Daniel	Chief Financial Officer	Dec 20 '23	Sale	7.93	57	452	8,375	Dec 21 04:01 PM
Stuglik Brian M	Director	Dec 19 '23	Sale	7.73	274	2,118	90,450	Dec 20 04:00 PM
Paterson Dan	President and CEO	Dec 19 '23	Sale	7.73	183	1,415	86,916	Dec 20 04:01 PM
Gagnon Robert E.	Director	Dec 19 '23	Sale	7.73	130	1,005	46,212	Dec 20 04:03 PM
Stuglik Brian M	Director	Dec 18 '23	Sale	7.64	487	3,721	90,724	Dec 20 04:00 PM
Gagnon Robert E.	Director	Dec 18 '23	Sale	7.64	284	2,170	46,342	Dec 20 04:03 PM
Paterson Dan	President and CEO	Dec 18 '23	Sale	7.64	244	1,864	87,099	Dec 20 04:01 PM
Calkins Daniel	Vice President of Finance	Oct 05 '23	Sale	7.30	5	36	8,432	Oct 10 04:31 PM
Calkins Daniel	Vice President of Finance	Sep 25 '23	Sale	9.40	25	235	8,437	Sep 25 04:46 PM
Calkins Daniel	Vice President of Finance	Sep 21 '23	Sale	9.31	232	2,160	8,462	Sep 25 04:46 PM
Stuglik Brian M	Director	Sep 19 '23	Sale	9.84	274	2,696	91,211	Sep 20 04:15 PM
Paterson Dan	President and CEO	Sep 19 '23	Sale	9.84	183	1,801	87,343	Sep 20 04:15 PM
Gagnon Robert E.	Director	Sep 19 '23	Sale	9.84	130	1,279	46,626	Sep 20 04:15 PM
Stuglik Brian M	Director	Sep 18 '23	Sale	9.91	478	4,737	91,485	Sep 20 04:15 PM
Gagnon Robert E.	Director	Sep 18 '23	Sale	9.91	278	2,755	46,756	Sep 20 04:15 PM
Paterson Dan	President and CEO	Sep 18 '23	Sale	9.91	240	2,378	87,526	Sep 20 04:15 PM
Calkins Daniel	Vice President of Finance	Jul 06 '23	Sale	8.02	5	40	8,694	Jul 10 04:05 PM
Calkins Daniel	Vice President of Finance	Jun 26 '23	Sale	8.17	26	212	8,422	Jun 28 04:11 PM
Stuglik Brian M	Chief Executive Officer	Jun 20 '23	Sale	10.30	275	2,832	91,963	Jun 21 04:23 PM
Paterson Dan	President and COO	Jun 20 '23	Sale	10.30	183	1,885	37,766	Jun 21 04:25 PM
Gagnon Robert E.	Director	Jun 20 '23	Sale	10.30	130	1,339	47,034	Jun 21 04:24 PM
Stuglik Brian M	Chief Executive Officer	Jun 16 '23	Sale	9.92	487	4,831	92,238	Jun 21 04:23 PM
Gagnon Robert E.	Director	Jun 16 '23	Sale	9.92	283	2,807	47,164	Jun 21 04:24 PM
Paterson Dan	President and COO	Jun 16 '23	Sale	9.92	244	2,420	37,949	Jun 21 04:25 PM

Open in Screener

PBYI

Puma Biotechnology Inc

May 02 • 04:00PM ET

4.96

Dollar change +0.01
Percentage change 0.20	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

PBYI Puma Biotechnology Inc daily Stock Chart

Held by: VTI VXF AVUV DFAS IWC AVSC FESM EES DFUS SQLV

Index	-	P/E	10.99	EPS (ttm)	0.45	Insider Own	28.05%	Shs Outstand	47.65M	Perf Week	1.64%
Market Cap	239.12M	Forward P/E	29.18	EPS next Y	0.17	Insider Trans	-0.82%	Shs Float	34.68M	Perf Month	-7.29%
Income	21.59M	PEG	-	EPS next Q	0.03	Inst Own	55.12%	Short Float	9.59%	Perf Quarter	1.43%
Sales	235.64M	P/S	1.01	EPS this Y	-42.22%	Inst Trans	-2.11%	Short Ratio	5.70	Perf Half Y	101.63%
Book/sh	1.12	P/B	4.42	EPS next Y	-34.62%	ROA	9.54%	Short Interest	3.33M	Perf Year	87.17%
Cash/sh	1.99	P/C	2.49	EPS next 5Y	-	ROE	57.54%	52W Range	2.13 - 7.73	Perf YTD	14.55%
Dividend Est.	-	P/FCF	8.90	EPS past 5Y	-	ROI	17.12%	52W High	-35.83%	Beta	1.09
Dividend TTM	-	Quick Ratio	1.50	Sales past 5Y	-0.59%	Gross Margin	73.40%	52W Low	132.86%	ATR (14)	0.31
Dividend Ex-Date	-	Current Ratio	1.57	EPS Y/Y TTM	15796.55%	Oper. Margin	14.12%	RSI (14)	43.40	Volatility	4.68% 5.56%
Employees	185	Debt/Eq	2.09	Sales Y/Y TTM	3.34%	Profit Margin	9.16%	Recom	3.00	Target Price	4.33
Option/Short	Yes / Yes	LT Debt/Eq	1.36	EPS Q/Q	308.66%	Payout	0.00%	Rel Volume	0.55	Prev Close	4.95
Sales Surprise	-10.70%	EPS Surprise	53.85%	Sales Q/Q	9.90%	Earnings	May 02 AMC	Avg Volume	583.63K	Price	4.96
SMA20	-5.17%	SMA50	-8.52%	SMA200	18.15%	Trades		Volume	319,771	Change	0.20%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-28-21	Upgrade	Citigroup	Neutral → Buy	$11
Jun-25-20	Resumed	BofA/Merrill	Underperform	$9
Oct-08-19	Downgrade	Goldman	Neutral → Sell	$24 → $8
May-10-19	Downgrade	Citigroup	Buy → Neutral	$24
May-10-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$57 → $20
Jan-17-19	Initiated	Leerink Partners	Mkt Perform	$21
Jan-03-19	Downgrade	Guggenheim	Buy → Neutral
Nov-19-18	Upgrade	Goldman	Sell → Neutral
Nov-02-18	Downgrade	JP Morgan	Neutral → Underweight
Nov-02-18	Downgrade	BofA/Merrill	Buy → Underperform
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight	$75
Sep-17-18	Initiated	Goldman	Sell	$42
May-11-18	Reiterated	Stifel	Buy	$95 → $87
Nov-10-17	Reiterated	RBC Capital Mkts	Sector Perform	$92 → $108
Nov-10-17	Reiterated	Citigroup	Buy	$156 → $164
Oct-02-17	Reiterated	Stifel	Buy	$110 → $130
Sep-11-17	Reiterated	Credit Suisse	Outperform	$118 → $136
Jul-10-17	Resumed	Leerink Partners	Outperform	$115
Jun-06-17	Reiterated	RBC Capital Mkts	Sector Perform	$60 → $88
May-25-17	Reiterated	RBC Capital Mkts	Sector Perform	$40 → $60

Show Previous Ratings

Today 06:05PM	Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:48PM	Puma Biotechnology Inc (PBYI) Reports Q1 Financial Results, Misses Analyst Revenue and EPS Forecasts (GuruFocus.com)
05:12PM	Puma Biotech: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports First Quarter Financial Results (Business Wire)
Apr-26-24 11:40AM	What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings? (Zacks)
10:02AM	Loading…
Apr-25-24 10:02AM	Earnings Preview: Puma Biotech (PBYI) Q1 Earnings Expected to Decline (Zacks)
Apr-18-24 04:15PM	Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results (Business Wire)
Apr-11-24 06:00PM	Puma Biotech (PBYI) Stock Dips While Market Gains: Key Facts (Zacks)
Apr-03-24 05:30PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-22-24 09:25AM	Puma Biotechnology (PBYI) Soars 14.0%: Is Further Upside Left in the Stock? (Zacks)
Mar-20-24 08:30AM	Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer (Business Wire) +9.19%
Mar-02-24 08:29AM	Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-01-24 09:55AM	Q4 2023 Puma Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) -5.31%
09:40AM	Why Puma Biotech (PBYI) is a Top Value Stock for the Long-Term (Zacks)
09:39AM	Puma Biotechnology (PBYI) Q4 Earnings & Revenues Lag Estimates (Zacks)
04:41PM	Loading…
Feb-29-24 04:41PM	Puma Biotechnology Inc (PBYI) Reports Positive Net Income for Q4 and Full Year 2023 (GuruFocus.com) -5.76%
04:40PM	Puma Biotech: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-27-24 06:30PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
11:51AM	Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store? (Zacks)
Feb-22-24 04:10PM	Puma Biotechnology to Participate in a Panel Discussion at TD Cowens 44th Annual Health Care Conference (Business Wire) -9.22%
Feb-15-24 04:10PM	Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results (Business Wire) -5.54%
Feb-13-24 08:30AM	Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer (Business Wire)
Jan-31-24 12:58PM	3 Strong Buy Stocks Under $5: January 2024 (InvestorPlace)
Jan-11-24 04:07PM	Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference (Business Wire)
Jan-06-24 11:02AM	Puma Biotechnology Inc CEO Alan Auerbach Sells 41,396 Shares (GuruFocus.com)
Dec-11-23 08:30AM	Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer (Business Wire) -7.99%
Nov-20-23 11:47AM	Here's Why You May Invest in Puma Biotechnology (PBYI) Stock (Zacks)
Nov-06-23 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-03-23 12:16PM	Puma Biotech (PBYI) Q3 Earnings Beat, Revenues Lag Estimates (Zacks) +11.65%
09:34AM	Loading…
09:34AM	Q3 2023 Puma Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents)
09:31AM	Puma Biotechnology, Inc. (NASDAQ:PBYI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 07:42PM	Puma Biotechnology Inc (PBYI) Reports Positive Net Income and Cash Flow in Q3 2023 (GuruFocus.com) -6.04%
04:47PM	Puma Biotech: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-19-23 04:14PM	Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results (Business Wire)
Oct-14-23 12:30PM	Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting (Business Wire)
Oct-04-23 05:30PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-22-23 07:57AM	Puma's (PBYI) Alisertib Gets FDA's Orphan Drug Tag for SCLC (Zacks)
Sep-21-23 04:10PM	Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer (Business Wire)
Aug-31-23 04:07PM	Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference (Business Wire)
Aug-08-23 08:30AM	Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer (Business Wire)
Aug-04-23 12:36PM	Puma Biotech (PBYI) Q2 Earnings Beat, Nerlynx Sales Outperform (Zacks) +8.52%
09:23AM	Q2 2023 Puma Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-03-23 05:17PM	Puma Biotech: Q2 Earnings Snapshot (AP Finance)
04:05PM	Puma Biotechnology Reports Second Quarter Financial Results (Business Wire)
Jul-20-23 04:15PM	Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results (Business Wire)
Jun-13-23 09:30AM	5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good (Zacks)
Jun-06-23 05:03PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-04-23 09:00AM	Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting (Business Wire)
May-28-23 10:06AM	Should You Be Concerned About Puma Biotechnology, Inc.'s (NASDAQ:PBYI) ROE? (Simply Wall St.)
May-22-23 11:07AM	Reasons to Add Puma (PBYI) Stock to Your Portfolio Right Now (Zacks) +5.54%
May-05-23 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +20.69%
12:45PM	Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Rise Y/Y (Zacks)
09:44AM	Q1 2023 Puma Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents)
May-04-23 05:32PM	Puma Biotech: Q1 Earnings Snapshot (AP Finance)
04:04PM	Puma Biotechnology Reports First Quarter Financial Results (Business Wire)
Apr-20-23 04:15PM	Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results (Business Wire)
Apr-17-23 06:49AM	Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34% (Simply Wall St.)
Apr-11-23 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-14-23 08:30AM	Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology (Business Wire)
Mar-06-23 09:48AM	Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2022 Earnings Call Transcript (Insider Monkey) -6.23%
Mar-03-23 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -19.35%
02:20PM	Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top (Zacks)
06:22AM	Q4 2022 Puma Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-02-23 04:05PM	Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results (Business Wire)
Feb-28-23 04:15PM	Puma Biotechnology to Participate in a Panel Discussion at Cowens 43rd Annual Health Care Conference (Business Wire)
Feb-19-23 02:05PM	7 A-Rated Penny Stocks Worth Betting On (InvestorPlace)
Feb-16-23 04:31PM	Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-07-23 05:30PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.31%
Feb-01-23 08:30AM	Puma Biotechnologys NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation (Business Wire)
Jan-25-23 06:19AM	Puma Biotechnology's (NASDAQ:PBYI) investors will be pleased with their decent 96% return over the last year (Simply Wall St.)
Jan-12-23 04:15PM	Puma Biotechnology to Present at B. Riley Securities 3rd Annual Oncology Conference (Business Wire)
Jan-11-23 05:30PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-09-23 08:55AM	Puma Biotechnology Releases Updated Corporate Presentation (Business Wire)
Dec-20-22 08:31AM	Institutional investors own a significant stake of 45% in Puma Biotechnology, Inc. (NASDAQ:PBYI) (Simply Wall St.)
Dec-15-22 03:39PM	Why Shares of Puma Biotechnology Rose This Week (Motley Fool)
Dec-07-22 06:03PM	Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium (Business Wire)
Dec-05-22 05:30PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-01-22 08:36AM	15 Best Affordable Stocks Under $30 (Insider Monkey)
Nov-28-22 09:55AM	Puma Biotech (PBYI)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
Nov-22-22 09:15AM	Puma Biotechnology, Inc. (PBYI) Hits Fresh High: Is There Still Room to Run? (Zacks)
08:50AM	Is Puma Biotechnology (PBYI) Stock a Solid Choice Right Now? (Zacks)
Nov-21-22 05:25PM	Why Puma Biotechnology's Shares Jumped 20% on Monday (Motley Fool) +20.00%
Nov-17-22 09:40AM	Is Biogen (BIIB) a Great Value Stock Right Now? (Zacks) +12.74%
Nov-14-22 10:10AM	Bayer (BAYRY) Eylea Label Extension Gets CHMP Positive Opinion (Zacks) +13.52%
09:50AM	Why Puma Biotech (PBYI) is a Top Momentum Stock for the Long-Term (Zacks)
Nov-11-22 10:20AM	Viatris (VTRS) Wins in Court Against AstraZeneca's Symbicort (Zacks)
Nov-09-22 10:43AM	Regeneron (REGN) Gets FDA Nod for Libtayo's Label Expansion (Zacks) -9.51%
06:02AM	Puma Biotechnology Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-07-22 01:02PM	Why Puma Biotechnology, Inc. (NASDAQ:PBYI) Looks Like A Quality Company (Simply Wall St.) +15.50%
Nov-04-22 12:29PM	Intra-Cellular (ITCI) Beat on Q3 Earnings and Sales Estimates (Zacks) +26.64%
12:20PM	Agios (AGIO) Q3 Loss Narrower Than Expected, Sales Miss (Zacks)
12:18PM	Intellia's (NTLA) Q3 Loss Wider Than Expected, Revenues Up Y/Y (Zacks)
11:18AM	Puma Biotech (PBYI) Q3 Earnings Top, Nerlynx Sales View Up (Zacks)
Nov-03-22 06:45PM	Puma Biotech (PBYI) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Puma Biotechnology Reports Third Quarter 2022 Financial Results (Business Wire)
Nov-02-22 05:30PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-27-22 04:05AM	Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium (Business Wire)
Oct-20-22 04:15PM	Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results (Business Wire)

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AUERBACH ALAN H	President and CEO	Jan 03 '24	Sale	4.49	41,396	185,698	6,936,947	Jan 05 06:56 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jan 03 '24	Sale	4.49	15,682	70,348	128,666	Jan 05 06:49 PM
Ludwig Jeffrey Jerome	Chief Commercial Officer	Jan 03 '24	Sale	4.49	12,956	58,119	99,970	Jan 05 07:00 PM
HUNT DOUGLAS M	See Remarks	Jan 03 '24	Sale	4.49	8,358	37,493	103,319	Jan 05 06:42 PM
Wong Alvin F	Chief Scientific Officer	Jan 03 '24	Sale	4.49	7,733	34,689	98,214	Jan 05 07:03 PM
Wong Alvin F	Chief Scientific Officer	Dec 04 '23	Sale	3.76	280	1,053	97,934	Jan 10 04:41 PM
MILLER MICHAEL PATRICK	Director	Nov 07 '23	Sale	2.83	25,000	70,802	43,358	Nov 09 04:19 PM
AUERBACH ALAN H	President and CEO	Jul 03 '23	Sale	3.31	60,698	200,983	6,978,343	Jul 06 07:03 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jul 03 '23	Sale	3.31	14,680	48,608	144,348	Jul 06 07:12 PM
Ludwig Jeffrey Jerome	Chief Commercial Officer	Jul 03 '23	Sale	3.31	12,103	40,075	112,926	Jul 06 07:08 PM
HUNT DOUGLAS M	See Remarks	Jul 03 '23	Sale	3.31	7,809	25,857	111,677	Jul 06 07:06 PM
Wong Alvin F	Chief Scientific Officer	Jul 03 '23	Sale	3.31	6,938	22,973	105,947	Jul 06 07:16 PM
Senderowicz Adrian	Director	Jun 13 '23	Sale	3.45	27,000	93,280	0	Jun 15 09:03 PM
WILSON TROY EDWARD	Director	Jun 13 '23	Sale	3.45	27,000	93,269	350	Jun 15 09:14 PM
MOYES JAY M	Director	Jun 13 '23	Sale	3.45	22,000	75,970	16,322	Jun 15 09:10 PM
MILLER MICHAEL PATRICK	Director	Jun 13 '23	Sale	3.45	13,500	46,630	41,358	Jun 15 08:28 PM
Dorval Allison	Director	Jun 13 '23	Sale	3.45	10,000	34,500	17,000	Jun 15 09:01 PM
Stuglik Brian M	Director	Jun 13 '23	Sale	3.46	9,900	34,252	31,958	Jun 15 09:06 PM
Wong Alvin F	Chief Scientific Officer	Jun 02 '23	Sale	3.45	269	928	112,885	Jun 06 04:36 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

VSTM

Verastem Inc

PBYI

Puma Biotechnology Inc

Upgrade your FINVIZ experience